Efficacy and safety of autologous stem cell transplantation in patients aged ≥ 65 years with multiple myeloma in the era of novel agents

Shohei Mizuno, Koji Kawamura, Ichiro Hanamura, Kazutaka Sunami, Takehiko Mori, Fumihiko Nakamura, Shinsuke Iida, Hideyuki Nakazawa, Masanori Makita, Shinichi Kako, Masashi Sawa, Yasunori Ueda, Hiroyuki Takahashi, Yoshinobu Kanda, Tatsuo Ichinohe, Yoshiko Atsuta, Hiroyuki Takamatsu, Akiyoshi Takami

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

Clinical trials evaluating the role of autologous hematopoietic stem cell transplantation (auto-HCT) in multiple myeloma have mostly included patients aged <65 years. Therefore, this study was aimed to evaluate the efficacy and safety of auto-HCT in elderly patients with multiple myeloma in the era of novel agents. We retrospectively analyzed 2056 patients with multiple myeloma, who underwent auto-HCT in 2007–2014 (287 were aged ≥65 years). We evaluated the 100-day treatment-related mortality (TRM) and overall survival (OS) in two groups; elderly patients (≥65 years) who underwent auto-HCT compared with younger patients (<65 years). In the propensity score–matched-pair analysis used to adjust for possible selection bias, the incidence of 100-day TRM between patients aged <65 (0.4%; 95% confidence interval [CI]: 0.0–2.0%) and ≥65 years (1.2%; 95% CI: 0.3–3.1%) showed no statistically significant difference (p = 0.31). The probability of the 5-year OS after transplantation in those aged <65 (62.5%; 95% CI: 58.6–66.1%) and ≥65 (63.5%; 95% CI: 52.2–72.7%) years was also not significantly different (p = 0.56). This study showed that the safety and efficacy of auto-HCT in elderly patients with multiple myeloma in the era of novel agents compared with younger patients were similar.

Original languageEnglish
Pages (from-to)1595-1604
Number of pages10
JournalBone Marrow Transplantation
Volume54
Issue number10
DOIs
Publication statusPublished - 2019 Oct 1

ASJC Scopus subject areas

  • Hematology
  • Transplantation

Fingerprint Dive into the research topics of 'Efficacy and safety of autologous stem cell transplantation in patients aged ≥ 65 years with multiple myeloma in the era of novel agents'. Together they form a unique fingerprint.

  • Cite this

    Mizuno, S., Kawamura, K., Hanamura, I., Sunami, K., Mori, T., Nakamura, F., Iida, S., Nakazawa, H., Makita, M., Kako, S., Sawa, M., Ueda, Y., Takahashi, H., Kanda, Y., Ichinohe, T., Atsuta, Y., Takamatsu, H., & Takami, A. (2019). Efficacy and safety of autologous stem cell transplantation in patients aged ≥ 65 years with multiple myeloma in the era of novel agents. Bone Marrow Transplantation, 54(10), 1595-1604. https://doi.org/10.1038/s41409-019-0478-4